Getinge stock trades steady as margin focus follows mixed start to 2026

Getinge B stock, issued by Swedish medtech group Getinge AB (ISIN SE0000202624), is trading against a backdrop of flat organic sales and tighter margins reported for Q1 2026, while cash flow and orders provide support for the valuation as of 24 April 2026 according to the companys quarterly update.

Q1 2026 sales stable at SEK 7.6 billion

According to Getinge ABs Q1 2026 report, net sales in the first quarter of 2026 amounted to SEK 7.6 billion, essentially unchanged on an organic basis compared with the same period a year earlier.

The report states that organic order intake in Q1 2026 grew by approximately 2%, highlighting continued demand for the groups medical technology equipment and related services even as reported sales stayed flat versus Q1 2025.

Operating margin at 10.7 percent in Q1 2026

In its Q1 2026 publication, Getinge reported an adjusted EBITA margin of 10.7% for Q1 2026, which was down from 12.1% in Q1 2025 as higher cost inflation and product mix weighed on profitability.

The company also disclosed that Q1 2026 operating profit based on EBITA came in at around SEK 0.8 billion, compared with roughly SEK 0.9 billion in the prior-year quarter, illustrating the impact of margin compression despite stable topline revenue.

Cash flow improves to SEK 0.9 billion

The same Q1 2026 document from Getinge AB shows that operating cash flow strengthened to approximately SEK 0.9 billion in Q1 2026, compared with about SEK 0.7 billion in Q1 2025, supported by improved working capital management.

Management indicated in the Q1 2026 commentary that the better cash generation gives Getinge additional flexibility to invest in product development and to manage its leverage profile, even as earnings margins declined year on year.

Medical Systems portfolio and ventilators

Getinge highlights its Medical Systems portfolio, notably intensive-care ventilators and anaesthesia machines, as a core contributor to revenue in recent years, with the segment having generated several billion SEK in annual sales during fiscal 2025 according to information made available via its 2025 annual report.

The companys documentation for fiscal 2025 explains that therapy-centric devices such as advanced ventilators and cardiac support equipment are crucial for hospital customers, and that this equipment underpins a substantial share of the groups recurring consumables and service revenue each year.

Getinge stock and recent valuation context

Market data from a Stockholm exchange-focused quote service as of 24 April 2026 shows Getinge B stock trading around SEK 250 per share, which places it roughly mid-range between its 52-week high near SEK 280 and 52-week low close to SEK 220 over the preceding twelve months.

Based on the same quote snapshot, Getinge ABs market capitalization stood at approximately SEK 66 billion as of 24 April 2026, reflecting investors pricing in moderate growth with an eye on margin normalization following the 10.7% Q1 2026 EBITA margin versus 12.1% a year earlier.